Key points
- The transcriptome is the full set of RNA molecules a cell produces. It shows which genes are active at a given time.
- Every cell has essentially the same genome, but different cell types and diseases have very different transcriptomes.
- RNA sequencing (RNA-seq) is now the main method for measuring the transcriptome.
- The GTEx project analyzed 15,201 RNA-sequencing samples from 49 tissues of 838 donors to map gene activity across the human body.
- Gene-expression tests are already used in care. In the TAILORx trial of 6,711 women with a midrange 21-gene recurrence score, endocrine therapy alone was noninferior to adding chemotherapy.
Almost every cell in your body carries the same DNA, yet a liver cell and a brain cell look and behave completely differently. The difference lies in which genes each cell switches on. Transcriptomics measures exactly that, by studying the RNA molecules cells make from their genes.
From DNA to RNA to protein
When a gene is switched on, the cell copies its DNA into a molecule called RNA, a process called transcription. One kind of RNA, messenger RNA (mRNA), carries the instructions to the cell's protein-making machinery. Other kinds of RNA do not make proteins at all but help regulate the cell.
The transcriptome is the complete set of RNA molecules in a cell or tissue at a particular moment. Unlike the genome, it changes constantly in response to development, environment, disease, and drugs.
| Layer | What it tells you | How stable it is |
|---|---|---|
| Genome (DNA) | Which genes a cell could use | Essentially fixed for life |
| Transcriptome (RNA) | Which genes a cell is using, and how much | Changes within hours |
| Proteome (proteins) | Which proteins are actually present and active | Changes, often more slowly than RNA |
Transcriptomics fills the gap between genomics and proteomics.
How the transcriptome is measured
Microarrays
Earlier studies used microarrays, glass slides covered with thousands of DNA probes. RNA from a sample binds to matching probes, and the strength of the signal shows how active each gene is. Microarrays can only measure genes they were designed to detect.
RNA sequencing
RNA-seq converts RNA into DNA and reads it with next-generation sequencing. Counting how many reads come from each gene measures its activity. A widely cited 2009 review in Nature Reviews Genetics described RNA-seq as providing a far more precise measurement of transcript levels than earlier methods, and noted that it was already changing views of how complex transcriptomes are. RNA-seq can also detect new transcripts, different versions of the same gene (isoforms), and fused genes, which matter in some cancers.
Single-cell and spatial methods
Standard RNA-seq measures an average across all the cells in a sample. Single-cell RNA-seq measures the transcriptome of individual cells, revealing rare cell types and how cells differ within a tumor or tissue. Spatial transcriptomics measures gene activity while preserving where each cell sits in the tissue.
Mapping gene activity across the body
The Genotype-Tissue Expression (GTEx) project built a reference map of gene activity in healthy human tissues. Its 2020 analysis in Science examined 15,201 RNA-sequencing samples from 49 tissues of 838 donors and linked genetic variants to differences in gene activity. The findings are freely available through the GTEx Portal.
For drug developers, resources like GTEx answer a basic question: where in the body is a target gene active? A target active only in the diseased tissue is more attractive than one active everywhere, which could cause side effects in other organs.
Uses in drug development
| Use | How transcriptomics helps |
|---|---|
| Understanding disease | Comparing gene activity in diseased and healthy tissue to find what has gone wrong |
| Target discovery | Identifying genes switched on specifically in the disease |
| Mechanism of action | Showing which genes and pathways a drug changes in cells or patients |
| Biomarkers | Finding gene-activity patterns that predict prognosis or response to treatment |
| Toxicology | Detecting early gene-activity changes that signal damage to organs |
Gene-expression tests in clinical care
Transcriptomic tests are already used to guide treatment. One of the best known measures the activity of 21 genes in breast tumors to produce a recurrence score.
The TAILORx trial, reported in the New England Journal of Medicine in 2018, enrolled 10,273 women with hormone-receptor-positive, HER2-negative, node-negative early breast cancer. Of the eligible women, 6,711 had a midrange recurrence score of 11 to 25 and were randomly assigned to endocrine therapy alone or with chemotherapy. Endocrine therapy alone was noninferior for invasive disease-free survival, although the analysis suggested some chemotherapy benefit for women 50 or younger with scores of 16 to 25. A gene-activity test helped identify many patients who could safely avoid chemotherapy.
Limitations
- RNA is not protein. RNA levels often correlate only loosely with protein levels, and proteins do most of the work.
- Snapshots. Gene activity changes quickly, so a single sample captures one moment.
- Sample handling. RNA degrades quickly, and how samples are collected and stored can change results.
- Cell mixtures. Bulk measurements average across many cell types, which can hide changes in rare cells.
- Association versus cause. A gene that is more active in disease may be a response to the disease rather than its cause.
Sources
- Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nature Reviews Genetics. 2009;10(1):57–63.Peer-reviewed
- GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science. 2020;369(6509):1318–1330.Peer-reviewed
- Sparano JA, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. New England Journal of Medicine. 2018;379(2):111–121.Peer-reviewed
- GTEx Portal.Registry
- FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource.Regulator
This article is for education. It is not medical advice and not investment advice. Figures are drawn from the sources above and describe historical averages, not the prospects of any particular drug. See our editorial standards and disclaimer.